LAM drug dosing clues sought in blood and urine
NCT ID NCT03304678
First seen Feb 20, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study aimed to find markers in blood and urine that could help doctors choose the right dose of sirolimus for women with LAM, a rare lung disease. Thirty-three women who were starting sirolimus gave samples before and after taking the drug for 3 and 9 months. The goal was to see which proteins changed with treatment, which could guide future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHANGIOLEIOMYOMATOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.